Recursion Pharmaceuticals (RXRX) Stock Forecast, Price Target & Predictions
RXRX Stock Forecast
Recursion Pharmaceuticals stock forecast is as follows: an average price target of $9.67 (represents a 68.17% upside from RXRX’s last price of $5.75) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
RXRX Price Target
RXRX Analyst Ratings
Hold
Recursion Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 04, 2024 | Gil Blum | Needham | $11.00 | $6.10 | 80.33% | 91.30% |
Sep 03, 2024 | Scott Schoenhaus | KeyBanc | $12.00 | $6.07 | 97.69% | 108.70% |
Sep 03, 2024 | Dennis Ding | Jefferies | $6.00 | $6.02 | -0.34% | 4.35% |
Jun 26, 2024 | Scott Schoenhaus | KeyBanc | $16.00 | $8.76 | 82.65% | 178.26% |
10
Recursion Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 3 | 4 |
Avg Price Target | - | $9.67 | $11.25 |
Last Closing Price | $5.75 | $5.75 | $5.75 |
Upside/Downside | -100.00% | 68.17% | 95.65% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 04, 2024 | Needham | Market Perform | Market Perform | Hold |
Sep 04, 2024 | Needham | Buy | Buy | Hold |
Sep 03, 2024 | KeyBanc | Overweight | Overweight | Hold |
Sep 03, 2024 | Cowen & Co. | Hold | Hold | Hold |
Sep 03, 2024 | Jefferies | Hold | Hold | Hold |
Jun 26, 2024 | KeyBanc | Overweight | Overweight | Hold |
May 10, 2024 | Needham | Buy | Buy | Hold |
Apr 09, 2024 | Needham | Buy | Buy | Hold |
Mar 04, 2024 | Needham | Buy | Buy | Hold |
Jan 17, 2024 | Needham | Buy | Buy | Hold |
10
Recursion Pharmaceuticals Financial Forecast
Recursion Pharmaceuticals Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.89M | $10.10M | $11.02M | $12.13M | $13.68M | $13.05M | $7.65M | $5.30M | $2.50M | $2.53M | $2.55M | $2.56M |
Avg Forecast | $30.00M | $35.00M | $5.00M | $5.00M | $20.83M | $11.40M | $12.22M | $12.97M | $12.19M | $18.72M | $11.96M | $11.10M | $19.90M | $11.24M | $11.87M | $12.81M | $23.80M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
High Forecast | $46.11M | $53.80M | $7.69M | $7.69M | $32.02M | $17.52M | $18.79M | $19.94M | $19.41M | $28.77M | $11.96M | $17.06M | $31.04M | $11.24M | $18.24M | $19.69M | $36.58M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
Low Forecast | $12.95M | $15.11M | $2.16M | $2.16M | $8.99M | $4.92M | $5.28M | $5.60M | $3.00M | $8.08M | $11.96M | $4.79M | $7.75M | $11.24M | $5.12M | $5.53M | $10.28M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.90% | 0.93% | 0.95% | 0.57% | 1.91% | 1.43% | 0.06% | 0.41% | 0.95% | 0.94% | 0.96% |
Forecast
Recursion Pharmaceuticals EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-98.93M | $-85.41M | $-81.72M | $-61.58M | $-60.98M | $-57.44M | $-62.76M | $-53.20M | $-62.70M | $-44.77M | $-38.57M | $-29.07M |
Avg Forecast | $-30.00M | $-35.00M | $-5.00M | $-5.00M | $-20.83M | $-11.40M | $-12.22M | $-12.97M | $-12.19M | $-18.72M | $-11.96M | $-11.10M | $-19.90M | $-11.24M | $-11.87M | $-12.81M | $-23.80M | $-6.84M | $-5.33M | $-253.75M | $-6.03M | $-2.67M | $-25.15M | $-2.67M |
High Forecast | $-12.95M | $-15.11M | $-2.16M | $-2.16M | $-8.99M | $-4.92M | $-5.28M | $-5.60M | $-3.00M | $-8.08M | $-11.96M | $-4.79M | $-7.75M | $-11.24M | $-5.12M | $-5.53M | $-10.28M | $-6.84M | $-5.33M | $-203.00M | $-6.03M | $-2.67M | $-20.12M | $-2.67M |
Low Forecast | $-46.11M | $-53.80M | $-7.69M | $-7.69M | $-32.02M | $-17.52M | $-18.79M | $-19.94M | $-19.41M | $-28.77M | $-11.96M | $-17.06M | $-31.04M | $-11.24M | $-18.24M | $-19.69M | $-36.58M | $-6.84M | $-5.33M | $-304.51M | $-6.03M | $-2.67M | $-30.18M | $-2.67M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 4.97% | 7.60% | 6.89% | 4.81% | 2.56% | 8.39% | 11.77% | 0.21% | 10.39% | 16.74% | 1.53% | 10.87% |
Forecast
Recursion Pharmaceuticals Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-93.00M | $-93.02M | $-76.73M | $-60.79M | $-57.48M | $-58.32M | $-65.55M | $-55.98M | $-64.95M | $-48.45M | $-45.87M | $-30.95M |
Avg Forecast | $-81.95M | $-73.47M | $-101.73M | $-98.90M | $-136.58M | $-139.17M | $-137.05M | $-136.35M | $-119.04M | $-94.05M | $-108.59M | $-119.63M | $-126.81M | $-108.90M | $-105.97M | $-98.50M | $-81.95M | $-91.73M | $-90.42M | $-267.02M | $-74.27M | $-67.81M | $-28.30M | $-57.32M |
High Forecast | $-21.41M | $-19.19M | $-26.58M | $-25.84M | $-35.68M | $-36.36M | $-35.80M | $-35.62M | $-98.63M | $-24.57M | $-28.37M | $-31.25M | $-82.70M | $-28.45M | $-27.68M | $-25.73M | $-21.41M | $-91.73M | $-90.42M | $-213.62M | $-74.27M | $-67.81M | $-22.64M | $-57.32M |
Low Forecast | $-139.17M | $-124.77M | $-172.76M | $-167.96M | $-231.95M | $-236.35M | $-232.75M | $-231.55M | $-142.85M | $-159.72M | $-184.42M | $-203.15M | $-162.65M | $-184.94M | $-179.95M | $-167.27M | $-139.17M | $-91.73M | $-90.42M | $-320.42M | $-74.27M | $-67.81M | $-33.97M | $-57.32M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.85% | 0.72% | 0.62% | 0.70% | 0.64% | 0.72% | 0.21% | 0.87% | 0.71% | 1.62% | 0.54% |
Forecast
Recursion Pharmaceuticals SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $30.46M | $29.20M | $28.29M | $22.87M | $19.84M | $19.49M | $21.20M | $21.07M | $19.20M | $15.69M | $13.85M | $8.94M |
Avg Forecast | $172.72M | $201.51M | $28.79M | $28.79M | $119.95M | $65.63M | $70.38M | $74.70M | $70.16M | $107.76M | $68.84M | $63.91M | $114.55M | $64.70M | $68.32M | $73.74M | $137.03M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
High Forecast | $265.49M | $309.74M | $44.25M | $44.25M | $184.37M | $100.89M | $108.19M | $114.83M | $111.78M | $165.65M | $68.84M | $98.23M | $178.72M | $64.71M | $105.01M | $113.35M | $210.63M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
Low Forecast | $74.57M | $87.00M | $12.43M | $12.43M | $51.78M | $28.34M | $30.39M | $32.25M | $17.26M | $46.52M | $68.84M | $27.59M | $44.63M | $64.70M | $29.50M | $31.83M | $59.16M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.27% | 0.45% | 0.41% | 0.31% | 0.14% | 0.49% | 0.69% | 0.04% | 0.55% | 1.02% | 0.88% | 0.58% |
Forecast
Recursion Pharmaceuticals EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.43 | $-0.38 | $-0.32 | $-0.31 | $-0.34 | $-0.38 | $-0.33 | $-0.38 | $-0.29 | $-0.33 | $-0.20 |
Avg Forecast | $-0.29 | $-0.26 | $-0.36 | $-0.35 | $-0.48 | $-0.49 | $-0.48 | $-0.48 | $-0.42 | $-0.33 | $-0.38 | $-0.42 | $-0.45 | $-0.39 | $-0.37 | $-0.35 | $-0.29 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
High Forecast | $-0.08 | $-0.07 | $-0.09 | $-0.09 | $-0.13 | $-0.13 | $-0.13 | $-0.13 | $-0.35 | $-0.09 | $-0.10 | $-0.11 | $-0.29 | $-0.10 | $-0.10 | $-0.09 | $-0.08 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
Low Forecast | $-0.49 | $-0.44 | $-0.61 | $-0.59 | $-0.82 | $-0.84 | $-0.82 | $-0.82 | $-0.51 | $-0.57 | $-0.65 | $-0.72 | $-0.58 | $-0.65 | $-0.64 | $-0.59 | $-0.49 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 1.12% | 1.01% | 0.92% | 1.07% | 0.90% | 1.02% | -3.30% | 1.24% | 1.04% | 1.41% | 0.85% |
Forecast
Recursion Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
RLAY | Relay Therapeutics | $4.64 | $19.40 | 318.10% | Buy |
IMMX | Immix Biopharma | $1.68 | $7.00 | 316.67% | Buy |
CNSP | CNS Pharmaceuticals | $0.13 | $0.50 | 284.62% | - |
SANA | Sana Bio | $2.35 | $8.00 | 240.43% | Buy |
ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
AFMD | Affimed | $2.64 | $7.50 | 184.09% | Buy |
ABSI | Absci | $2.55 | $6.00 | 135.29% | Buy |
RXRX | Recursion Pharmaceuticals | $5.75 | $9.67 | 68.17% | Hold |
VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |